Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CVRX
STRONG SELLCVRx, Inc. · Healthcare · United States · $126M · Avg Vol: $1M/d
COMPANY DESCRIPTION
CVRx, Inc. is a medical device company focused on developing and commercializing its proprietary Barostim™ neuromodulation technology to treat cardiovascular diseases like heart failure and hypertension. Its unique, FDA-approved implantable device offers a novel therapeutic option for patients with advanced heart failure who remain symptomatic despite conventional treatments, establishing a significant market niche.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22.5M | 39.3M | 51.3M | 56.7M | 36.1% | 59.1M | 65.3M | 76.2M | 16.0% |
| EPS | -2.02 | -1.99 | -2.65 | -2.04 | — | -1.95 | -1.96 | -1.89 | — |
| Shares | 20.6M | 20.9M | 25.3M | 26.3M | +27.5% | 26.5M | — | — | — |
| Debt | 7.1M | 30.6M | 50.4M | 50.5M | 92.4% | 59.4M | — | — | — |
| Equity | 109.2M | 75.9M | 71.1M | 39.3M | -28.9% | — | — | — | — |
| Op CF | -42.7M | -39.0M | -39.1M | -40.2M | — | -39.6M | — | — | — |
| Inv CF | -0.7M | -0.6M | -1.4M | -0.6M | — | — | — | — | — |
| Fin CF | 7.5M | 24.0M | 55.9M | 10.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CVRX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CVRX | CVRx, Inc.(you) | $126M | 12 | STRONG SELL |
| STIM | Neuronetics, Inc. | $120M | 15 | STRONG SELL |
| OWLT | Owlet, Inc. | $153M | 11 | STRONG SELL |
| HYPR | Hyperfine, Inc. | $95M | 13 | STRONG SELL |
| QSI | Quantum-Si incorporated | $168M | 11 | STRONG SELL |
| AVH.AX | AVITA Medical, Inc. | $115M | 19 | STRONG SELL |
| LUCD | Lucid Diagnostics Inc. | $173M | 9 | STRONG SELL |
| EBR.AX | EBR Systems, Inc. | $115M | 1 | STRONG SELL |
| LNSR | LENSAR, Inc. | $69M | 11 | STRONG SELL |
| RPID | Rapid Micro Biosystems, Inc. | $99M | 4 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.5%